Interview with Amarastesia | CerAMvix: Rethinking Cervical Access in Gynaecology
Amarastesia is developing CerAMvix, an innovative cervical access device designed to make gynaecological procedures safer, less traumatic and more patient-centred.
Built around female anatomy and physiology, CerAMvix aims to address some of the long-standing limitations of conventional cervical dilation. By replacing rigid, force-based instrumentation with a flexible, self-expanding approach, the technology seeks to reduce trauma while creating a protected passageway for instruments during procedures such as hysteroscopy.
We spoke with the Amarastesia team, and to its CEO, Roxana Belciu-Kerns to learn more about the clinical experiences that inspired CerAMvix, how the technology works, the impact it could have on patients and clinicians, and how Innosuisse funding will support the company’s path towards regulatory approval and market access.
1. Roxana, you witnessed complications such as uterine perforations and lacerations first-hand. How did those experiences lead to the creation of Amarastesia and CerAMvix?
Starting with the patient and female anatomy and understanding the failures of current standard of care devices. The lack of innovation in gynaecology stems from the unilateral borrowed instruments from other surgical fields when the female anatomy and physiology is very little accounted for. CerAMvix is a transformative step in rethinking uterine access with a patient centric device designed with female anatomy and physiology in mind.
2. Half of all hysteroscopy complications occur during cervical dilation. Why have conventional dilators changed so little, and what makes CerAMvix different?
Hysteroscopy in itself, has evolved with miniaturized instruments, but the patient centricity has not been addressed. Hysterocopes continue to be rigid, using axial excessive force prone to perforations and lacerations. CerAMvix accounts not only for female centricity but the evolution of materials used in medical devices, transforming rigid tools into flexible devices, with soft tapered access tip to minimize trauma and using self-expanding superelastic properties in nitinol to create a passthrough channel for safe instrumentation.
3. How do the protected instrument passageway and direct visualisation work together to improve safety and comfort during a procedure?
The CerAMvix dilator creates visibility by opening up tissues with a radial equally distributed physiological force, allowing clear passageway for instruments to pass through without the possibility of false passages or cervical lacerations.
4. Pain causes up to 84% of unsuccessful procedures. How could CerAMvix change the experience for patients and the daily work of gynaecologists?
Pain is subjective and hard to assess in clinical settings. But eliminating the major triggering factors for pain in cervical access such as forceful dilatation, repetitive instrumentation, rigid instrumentation with zero visibility, will definitely create softer responses better tolerated by patients. This will also translate in faster procedures with optimized workflow for clincians.
5. What are the key milestones the Innosuisse funding will help you reach on the way to regulatory approval and market launch?
Regulatory approval and initial market access. Expanding team to support R&D, QA and product launch.
6. How was your experience working with Evolution Europe during the Innosuisse application process, and what value did our team bring to the project?
As a physician and CEO I understand the clinical and economic value of CerAMvix but translating this into a written proposal for funding involves certain skills a startup alone cannot get through. Evolution and its team provided the expertise, structure, refinement needed to elevate a proposal from application to grant.into a successful grant.